EUVIMEDEUVIMED entdecken
VergleichsstudieKontrollierte klinische StudieOpen Access · CC BY 4.0

Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD

Luigi Schiavo iD, Biagio Santella, Monica Mingo, Gianluca Rossetti, Marcello Orio, Vincenzo Pilone

Nutrients · 24.07.2025 · 17 (15) · 2409

DOI: 10.3390/nu17152409 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nutrients, online erschienen am 24.07.2025. Verfasst von Luigi Schiavo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. Hauptthemen laut MEDLINE: Caloric Restriction, Diet, Ketogenic, Fatty Liver. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver condition globally, strongly linked to obesity, insulin resistance, and type 2 diabetes (T2D). Tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, improves glycemic control and reduces body weight and the liver fat content in patients with obesity and T2D. However, its effect on liver-specific outcomes such as steatosis and fibrosis remains incompletely characterized. Low-energy ketogenic therapy (LEKT), a nutritional strategy characterized by carbohydrate restriction and nutritional ketosis, may enhance hepatic β-oxidation and reduce hepatic lipogenesis. To date, however, the combination of TZP and LEKT has not been studied in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). This study aimed to compare the hepatic and metabolic effects of TZP combined with either LEKT or a conventional low-calorie diet (LCD) over a 12-week period.

Methods

Sixty adult patients with MASLD undergoing TZP therapy were prospectively assigned to either an LEKT or a conventional LCD, with 30 participants per group. As primary endpoints, the controlled attenuation parameter (CAP, an index of hepatic steatosis) and liver stiffness measurement (LSM, an index of liver fibrosis) were assessed at the baseline and after 12 weeks using FibroScan®. Secondary outcomes included changes in body mass index (BMI), glycated hemoglobin (HbA1c), and liver enzymes. Adherence to both diet and pharmacological treatment, as well as tolerability, were systematically monitored throughout the intervention period.

Results

Both groups showed significant reductions in body weight (TZP + LEKT, p = 0.0289; TZP + LCD, p = 0.0278), with no significant intergroup difference (p = 0.665). CAP and LSM improved significantly in both groups, but reductions were greater in the TZP + LEKT group (CAP −12.5%, p < 0.001; LSM −22.7%, p < 0.001) versus LCD (CAP −6.7%, p = 0.014; LSM −9.2%, p = 0.022). Between-group differences were statistically significant for both CAP (p = 0.01) and LSM (p = 0.03).

Conclusions

Based on these preliminary findings, we support the hypothesis that the combination of TZP and LEKT may be superior to TZP with an LCD in reducing hepatic steatosis and stiffness in individuals with obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Caloric RestrictionDiet, KetogenicFatty LiverAdultAgedFemaleHumansMaleMiddle AgedDiabetes Mellitus, Type 2LiverProspective StudiesTirzepatideTreatment OutcomeWeight Loss

Stichwörter der Autor:innen

FibroScanMASLDhepatic steatosisketogenic dietliver stiffnessnutritional ketosistirzepatide

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
  • National Biodiversity Future Center (NBFC), 90133 Palermo, Italy.
  • General and Bariatric Surgery Unit, Abano Terme Policlinic, 35031 Padova, Italy.
  • Medical and Diabetological Center (CMSO), 84123 Salerno, Italy.
  • Public Health Department, University of Naples Federico II, 80131 Naples, Italy.

ORCID-Profile: Luigi Schiavo

Zitieren

APA

Schiavo, L., Santella, B., Mingo, M., Rossetti, G., Orio, M., & Pilone, V. (2025). Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD. Nutrients, 17(15), 2409. https://doi.org/10.3390/nu17152409

Vancouver

Schiavo L, Santella B, Mingo M, Rossetti G, Orio M, Pilone V. Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD. Nutrients. 2025;17(15):2409. doi:10.3390/nu17152409

BibTeX
@article{Schiavo2025,
  author = {Schiavo, Luigi and Santella, Biagio and Mingo, Monica and Rossetti, Gianluca and Orio, Marcello and Pilone, Vincenzo},
  title = {Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD},
  journal = {Nutrients},
  year = {2025},
  volume = {17},
  number = {15},
  pages = {2409},
  doi = {10.3390/nu17152409}
}
Kostenlos starten →